Actively Recruiting
Liver Damage and Cardiometabolic Disorders in NAFLD
Led by University of Roma La Sapienza · Updated on 2019-08-16
2000
Participants Needed
1
Research Sites
1313 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Liver fibrosis is the most important prognostic factor in patients with non-alcoholic factor disease. Clinical and biological condition, as diabetes or mutation for PNPLA3, are well known factors associated with liver fibrosis onset and progression. However, little is known about biochemical factors predicting liver fibrosis evolution in large NAFLD populations.
CONDITIONS
Official Title
Liver Damage and Cardiometabolic Disorders in NAFLD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 years old or more
- Patients with at least one of the following metabolic disorders: obesity, diabetes, arterial hypertension, or dyslipidemia
You will not qualify if you...
- Average daily alcohol consumption more than 20 g in women and more than 30 g in men
- Presence of hepatitis B surface antigen or antibody to hepatitis C virus
- Positive tests for autoimmune hepatitis
- Diagnosis of cirrhosis or other chronic liver diseases
- Diagnosis of oncological diseases
- Concomitant therapy with drugs known to promote liver steatosis such as amiodarone
- Other chronic infectious or autoimmune diseases
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Day Service of Internal Medicine and Metabolic Disorders - Policlinico Umberto I - Sapienza University of Rome
Rome, Italy, 00100
Actively Recruiting
Research Team
F
Francesco Baratta, MD, PI.
CONTACT
D
Daniele Pastori, MD, PI.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here